Previous 10 | Next 10 |
2023-11-16 07:18:38 ET More on Chimerix Chimerix: Dangerous Road, Thesis Intact Chimerix Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Chimerix For further details see: Chimerix names Thomas Riga as Chief Operating and Commercial Officer
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commer...
2023-11-08 08:34:45 ET Lumos Pharma ( LUMO ) +36% Q3 earnings call release Target Hospitality ( TH ) +25% Q3 earnings call release Baiyu Holdings ( BYU ) +23% . Upwork ( UPWK ) +23% Q3 earnings call release EVgo ( E...
2023-11-02 14:50:11 ET Chimerix, Inc. (CMRX) Q3 2023 Earnings Conference Call November 02, 2023 08:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning & Investor Relations Mike Andriole - President & Chief Executive Officer...
2023-11-02 07:21:46 ET More on Chimerix Chimerix: Dangerous Road, Thesis Intact Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript Chimerix, Inc. 2023 Q2 - Results - Earnings Call Presentation Chimerix Q3 2023 Earnings Preview Seeking Alpha’...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conf...
Chimerix Inc. (CMRX) is expected to report $-0.22 for Q3 2023
2023-11-01 13:02:11 ET More on Chimerix Chimerix: Dangerous Road, Thesis Intact Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript Chimerix, Inc. 2023 Q2 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Chimerix Histor...
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webc...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data...